China Hunter Syndrome Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Hunter syndrome is a rare, inherited disorder in which the body does not properly digest (break down) sugar molecules in the body. When these molecules build up in organs and tissues over time, they can cause damage that affects physical and mental development and abilities. It occurs in approximately 1.3 out of 100,000 male new-borns in China. Currently in China the median age of onset is under 5 years and the median age of death, typically from heart or respiratory failure is 15.
China is a growing market for Hunter syndrome disease due to increasing government initiatives, the introduction of novel therapies, and robust pipelines. In addition to these factors, growing awareness about hunter syndrome and the availability of therapeutic options may propel the revenue growth of the market. China market is likely to witness a faster growth owing to rapid developments in healthcare infrastructure and significant investments.
However, there are some restraining factors for the growth of lysosomal storage disorders therapeutics market in China such as high cost of treatment, limitations of medical insurance coverage and misdiagnosis of the disease.